{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:26:11Z","timestamp":1788279971764,"version":"build-2803163510"},"reference-count":86,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.ekir.2023.04.016","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T12:14:55Z","timestamp":1682338495000},"page":"1290-1300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Managing Hyperkalemia in the Modern Era: A Case-Based Approach"],"prefix":"10.1016","volume":"8","author":[{"given":"David","family":"Massicotte-Azarniouch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Canney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish M.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory L.","family":"Hundemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2023.04.016_bib1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13613-019-0509-8","article-title":"Management of hyperkalemia in the acutely ill patient","volume":"9","author":"D\u00e9pret","year":"2019","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.ekir.2023.04.016_bib2","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jemermed.2020.11.028","article-title":"An evidence-based narrative review of the emergency department management of acute hyperkalemia","volume":"60","author":"Lemoine","year":"2021","journal-title":"J\u00a0Emerg Med"},{"key":"10.1016\/j.ekir.2023.04.016_bib3","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJM199005033221806","article-title":"Pseudohyperkalemia caused by fist clenching during phlebotomy","volume":"322","author":"Don","year":"1990","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2023.04.016_bib4","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1053\/ajkd.2000.19084","article-title":"Factitious hyperkalemia","volume":"36","author":"Wiederkehr","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2023.04.016_bib5","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0272-6386(88)80005-2","article-title":"Thrombocytosis elevates serum potassium","volume":"12","author":"Graber","year":"1988","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2023.04.016_bib6","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1053\/j.ajkd.2005.06.005","article-title":"Pseudohyperkalemia due to pneumatic tube transport in a leukemic patient","volume":"46","author":"Kellerman","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2023.04.016_bib7","doi-asserted-by":"crossref","first-page":"326","DOI":"10.5414\/CNP59326","article-title":"Serum potassium in the crush syndrome victims of the Marmara disaster","volume":"59","author":"Sever","year":"2003","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ekir.2023.04.016_bib8","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2023.04.016_bib9","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S0140-6736(78)90801-2","article-title":"Glucose-induced hyperkalaemia: a hazard for diabetics?","volume":"1","author":"Viberti","year":"1978","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2023.04.016_bib10","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/0002-9343(81)90182-0","article-title":"Changes in plasma potassium concentration during acute acid-base disturbances","volume":"71","author":"Adrogu\u00e9","year":"1981","journal-title":"Am J Med"},{"key":"10.1016\/j.ekir.2023.04.016_bib11","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2215\/CJN.07821109","article-title":"Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors","volume":"5","author":"Weir","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.04.016_bib12","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2023.04.016_bib13","first-page":"CD007004","article-title":"Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease","volume":"10","author":"Chung","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ekir.2023.04.016_bib14","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and Type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2023.04.016_bib15","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in Type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2023.04.016_bib16","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.3874","article-title":"Association of changes in creatinine and potassium levels after initiation of renin angiotensin aldosterone system inhibitors with emergency department visits, hospitalizations, and mortality in individuals with chronic kidney disease","volume":"1","author":"Garlo","year":"2018","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ekir.2023.04.016_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.824095","article-title":"RAAS inhibitor prescription and hyperkalemia event in patients with chronic kidney disease: a single-center retrospective study","volume":"9","author":"Riccio","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.ekir.2023.04.016_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213192","article-title":"Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: a general practice-based, observational study","volume":"14","author":"Jun","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2023.04.016_bib19","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2023.04.016_bib20","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ekir.2023.04.016_bib21","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1053\/j.ajkd.2005.08.018","article-title":"Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes","volume":"46","author":"Winkelmayer","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2023.04.016_bib22","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3109\/0886022X.2012.717478","article-title":"Major barriers against renin-angiotensin-aldosterone system blocker use in chronic kidney disease stages 3-5 in clinical practice: a safety concern?","volume":"34","author":"Yildirim","year":"2012","journal-title":"Ren Fail"},{"key":"10.1016\/j.ekir.2023.04.016_bib23","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1053\/ajem.2000.7344","article-title":"Electrocardiographic manifestations of hyperkalemia","volume":"18","author":"Mattu","year":"2000","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.ekir.2023.04.016_bib24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.kisu.2016.01.003","article-title":"Electrophysiological and clinical consequences of hyperkalemia","volume":"6","author":"Campese","year":"2016","journal-title":"Kidney Int Suppl (2011)"},{"key":"10.1016\/j.ekir.2023.04.016_bib25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0022-0736(99)90020-1","article-title":"Severe hyperkalemia with minimal electrocardiographic manifestations: a report of seven cases","volume":"32","author":"Martinez-Vea","year":"1999","journal-title":"J\u00a0Electrocardiol"},{"key":"10.1016\/j.ekir.2023.04.016_bib26","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.kint.2019.09.018","article-title":"Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: improving Global Outcomes (KDIGO) Controversies Conference","volume":"97","author":"Clase","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2023.04.016_bib27","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2215\/CJN.05850809","article-title":"Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study","volume":"5","author":"Korgaonkar","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.04.016_bib28","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/eurheartj\/ehy100","article-title":"Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis","volume":"39","author":"Kovesdy","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ekir.2023.04.016_bib29","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.kisu.2016.01.004","article-title":"Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena","volume":"6","author":"Epstein","year":"2016","journal-title":"Kidney Int Suppl (2011)"},{"key":"10.1016\/j.ekir.2023.04.016_bib30","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.ajkd.2022.01.002","article-title":"Hyperkalemia-related discontinuation of renin-angiotensin-aldosterone system inhibitors and clinical outcomes in CKD: a population-based cohort study","volume":"80","author":"Leon","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2023.04.016_bib31","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1001\/jamainternmed.2020.0193","article-title":"Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate","volume":"180","author":"Qiao","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ekir.2023.04.016_bib32","article-title":"Real-world associations of renin-angiotensin-aldosterone system inhibitor dose, hyperkalemia, and adverse clinical outcomes in a cohort of patients with new-onset chronic kidney disease or heart failure in the United Kingdom","volume":"8","author":"Linde","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.ekir.2023.04.016_bib33","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","article-title":"Renin-angiotensin system inhibition in advanced chronic kidney disease","volume":"387","author":"Bhandari","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2023.04.016_bib34","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2023.04.016_bib35","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.04.016_bib36","doi-asserted-by":"crossref","first-page":"m4573","DOI":"10.1136\/bmj.m4573","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"372","author":"Palmer","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ekir.2023.04.016_bib37","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ahj.2020.10.064","article-title":"Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials","volume":"232","author":"Salah","year":"2021","journal-title":"Am Heart J"},{"key":"10.1016\/j.ekir.2023.04.016_bib38","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ekir.2023.04.016_bib39","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1161\/CIRCULATIONAHA.118.037076","article-title":"24-hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA study","volume":"139","author":"Kario","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2023.04.016_bib40","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/dc14-1096","article-title":"Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension","volume":"38","author":"Tikkanen","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2023.04.016_bib41","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1161\/CIRCULATIONAHA.118.036568","article-title":"Antihyperglycemic and blood pressure effects of empagliflozin in black patients with type 2 diabetes mellitus and hypertension","volume":"139","author":"Ferdinand","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2023.04.016_bib42","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archinte.158.1.26","article-title":"Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?","volume":"158","author":"Reardon","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ekir.2023.04.016_bib43","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2215\/CJN.12990820","article-title":"Ambulatory treatments for RAAS inhibitor-related hyperkalemia and the 1-year risk of recurrence","volume":"16","author":"Hundemer","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.04.016_bib44","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/bmj.4.5834.196","article-title":"High dosage metolazone in chronic renal failure","volume":"4","author":"Dargie","year":"1972","journal-title":"Br Med J"},{"key":"10.1016\/j.ekir.2023.04.016_bib45","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa2110730","article-title":"Chlorthalidone for hypertension in advanced chronic kidney disease","volume":"385","author":"Agarwal","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2023.04.016_bib46","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/bmj.280.6218.905","article-title":"Hypokalaemia and diuretics: an analysis of publications","volume":"280","author":"Morgan","year":"1980","journal-title":"Br Med J"},{"key":"10.1016\/j.ekir.2023.04.016_bib47","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/ajh.2010.1","article-title":"Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium","volume":"23","author":"Ernst","year":"2010","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ekir.2023.04.016_bib48","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2023.04.016_bib49","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2023.04.016_bib50","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2023.04.016_bib51","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on water and sodium metabolism","volume":"13","author":"Tang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ekir.2023.04.016_bib52","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in heart failure: diuretic and cardiorenal effects","volume":"142","author":"Griffin","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2023.04.016_bib53","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.2337\/dc20-2265","article-title":"Changes in cardiovascular biomarkers associated with the sodium-glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin in patients with chronic kidney disease and type 2 diabetes","volume":"44","author":"Lawler","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2023.04.016_bib54","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.2215\/CJN.03640415","article-title":"Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD","volume":"10","author":"Lepage","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.04.016_bib55","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/ndt\/gfz150","article-title":"Initiation of sodium polystyrene sulphonate and the risk of gastrointestinal adverse events in advanced chronic kidney disease: a nationwide study","volume":"35","author":"Laureati","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2023.04.016_bib56","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamainternmed.2019.0631","article-title":"Risk of hospitalization for serious adverse gastrointestinal events associated with sodium polystyrene sulfonate use in patients of advanced age","volume":"179","author":"Noel","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ekir.2023.04.016_bib57","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1345\/aph.1M547","article-title":"Intestinal necrosis associated with orally administered calcium polystyrene sulfonate without sorbitol","volume":"45","author":"Goutorbe","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ekir.2023.04.016_bib58","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/sj.jp.7211677","article-title":"Necrotizing enterocolitis in a 850 gram infant receiving sorbitol-free sodium polystyrene sulfonate (Kayexalate): clinical and histopathologic findings","volume":"27","author":"Rugolotto","year":"2007","journal-title":"J\u00a0Perinatol"},{"key":"10.1016\/j.ekir.2023.04.016_bib59","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.3346\/jkms.2009.24.6.1207","article-title":"Colonic mucosal necrosis following administration of calcium polystryrene sulfonate (kalimate) in a uremic patient","volume":"24","author":"Joo","year":"2009","journal-title":"J\u00a0Korean Med Sci"},{"key":"10.1016\/j.ekir.2023.04.016_bib60","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","article-title":"Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2023.04.016_bib61","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2023.04.016_bib62","doi-asserted-by":"crossref","first-page":"798","DOI":"10.2215\/CJN.12651018","article-title":"Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month Phase 3 study","volume":"14","author":"Spinowitz","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.04.016_bib63","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","article-title":"Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ekir.2023.04.016_bib64","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1001\/jama.2014.15688","article-title":"Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial","volume":"312","author":"Kosiborod","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2023.04.016_bib66","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ekir.2022.12.005","article-title":"Association between dietary potassium intake estimated from multiple 24-hour urine collections and serum potassium in patients with CKD","volume":"8","author":"Ogata","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2023.04.016_bib67","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.2215\/CJN.08360621","article-title":"Dietary potassium intake and all-cause mortality in adults treated with hemodialysis","volume":"16","author":"Bernier-Jean","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.04.016_bib68","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1093\/ndt\/gfaa232","article-title":"Does dietary potassium intake associate with hyperkalemia in patients with chronic kidney disease?","volume":"36","author":"Ramos","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2023.04.016_bib69","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1053\/j.ajkd.2010.03.022","article-title":"Dietary potassium intake and mortality in long-term hemodialysis patients","volume":"56","author":"Noori","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2023.04.016_bib70","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1681\/ASN.2022020147","article-title":"Effects of short-term potassium chloride supplementation in patients with CKD","volume":"33","author":"Gritter","year":"2022","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.04.016_bib71","first-page":"438","article-title":"Dietary intake in hemodialysis patients does not reflect a heart healthy diet","volume":"21","author":"Khoueiry","year":"2011","journal-title":"J\u00a0Ren Nutr"},{"key":"10.1016\/j.ekir.2023.04.016_bib72","first-page":"282","article-title":"Nutrient non-equivalence: does restricting high-potassium plant foods help to prevent hyperkalemia in hemodialysis patients?","volume":"26","author":"St-Jules","year":"2016","journal-title":"J\u00a0Ren Nutr"},{"key":"10.1016\/j.ekir.2023.04.016_bib73","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.xkme.2020.04.007","article-title":"Impact of dietary potassium restrictions in CKD on clinical outcomes: benefits of a plant-based diet","volume":"2","author":"Clegg","year":"2020","journal-title":"Kidney Med"},{"key":"10.1016\/j.ekir.2023.04.016_bib74","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1053\/j.ajkd.2016.09.015","article-title":"Dialysate potassium, serum potassium, mortality, and arrhythmia events in hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"69","author":"Karaboyas","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2023.04.016_bib75","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/1744-9987.13622","article-title":"Cardiac arrhythmia during early-week and mid-week dialysis in hemodialysis patients","volume":"25","author":"Vareesangthip","year":"2021","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.ekir.2023.04.016_bib76","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1159\/000489961","article-title":"Dialysate potassium and mortality in a prospective hemodialysis cohort","volume":"47","author":"Ferrey","year":"2018","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ekir.2023.04.016_bib77","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1042\/cs0730247","article-title":"Evidence for large intestinal control of potassium homoeostasis in uraemic patients undergoing long-term dialysis","volume":"73","author":"Sandle","year":"1987","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.ekir.2023.04.016_bib78","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1042\/cs0710393","article-title":"Enhanced rectal potassium secretion in chronic renal insufficiency: evidence for large intestinal potassium adaptation in man","volume":"71","author":"Sandle","year":"1986","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.ekir.2023.04.016_bib79","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/path.1750","article-title":"Enhanced large intestinal potassium permeability in end-stage renal disease","volume":"206","author":"Mathialahan","year":"2005","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.ekir.2023.04.016_bib80","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1681\/ASN.2020081120","article-title":"Laxative use and risk of dyskalemia in patients with advanced CKD transitioning to dialysis","volume":"32","author":"Sumida","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.04.016_bib81","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/ndt\/18.2.341","article-title":"Dietary potassium and laxatives as regulators of colonic potassium secretion in end-stage renal disease","volume":"18","author":"Mathialahan","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2023.04.016_bib82","doi-asserted-by":"crossref","first-page":"G159","DOI":"10.1152\/ajpgi.00132.2009","article-title":"Regulation of colonic apical potassium (BK) channels by cAMP and somatostatin","volume":"297","author":"Perry","year":"2009","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.ekir.2023.04.016_bib83","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-12-2011-5451","article-title":"Ischaemic colitis associated with oral contraceptive and Bisacodyl use","volume":"2012","author":"Ajani","year":"2012","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.ekir.2023.04.016_bib84","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1111\/j.1572-0241.2005.50395_8.x","article-title":"Colonic ischemia with laxative use in young adults","volume":"100","author":"Lopez Morra","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ekir.2023.04.016_bib85","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/ajg.2009.637","article-title":"Recurrent ischemic colitis induced by colonoscopy bowel lavage","volume":"105","author":"Baudet","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ekir.2023.04.016_bib86","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1093\/ckj\/sfac129","article-title":"Comparative efficacy of patiromer and sodium polystyrene sulfonate on potassium levels in chronic haemodialysis patients: a randomized crossover trial","volume":"15","author":"Jaques","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2023.04.016_bib87","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1681\/ASN.2019050450","article-title":"A\u00a0Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of predialysis hyperkalemia","volume":"30","author":"Fishbane","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024923012718?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024923012718?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:45:08Z","timestamp":1762832708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024923012718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":86,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S2468024923012718"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2023.04.016","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing Hyperkalemia in the Modern Era: A Case-Based Approach","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2023.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}